Posts tagged Nuvama
| Royal Orchid Hotels will outpace peers & narrow valuation gap with its peers. Buy for target price of Rs 498 (76% upside): Nuvama | |
| Company: | Royal Orchid Hotels |
| Brokerage: | Nuvama |
| Date of report: | November 14, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 76% |
| Summary: | Strong room addition pipeline one of the key growth drivers. Expect revenue/EBITDA to clock 29%/18% CAGR over FY23–25 |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Royal Orchid Hotels |
| Elecon Engineering’s strong margin trend continues. It is a ‘tactical BUY’ for target price of Rs 874: Nuvama | |
| Company: | Elecon Engineering |
| Brokerage: | Nuvama |
| Date of report: | October 23, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 12% |
| Summary: | We reaffirm our ‘tactical BUY’ rating, but raise the TP to INR874 (from INR777), valuing the stock at 25x FY25E P/E (from 24x FY25E P/E). We have tweaked our FY24 and FY25 estimates to account for a better margin performance. The stock is trading at 26x/22x FY24E/FY25E P/E |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Elecon Engineering |
| Gati is turning over a new leaf. Buy for target price of Rs 234 (58% upside): Nuvama | |
| Company: | gati |
| Brokerage: | Nuvama |
| Date of report: | October 13, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 58% |
| Summary: | Gati (GTIC) has emerged as one of India’s leading multi-modal express logistics players. It operates in two segments — express logistics and fuel stations, which contribute 85% and 15% to total revenue, respectively. We initiate coverage with a ‘BUY’ rating and a DCF-based fair value of INR234, implying an upside of 58% from its CMP |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | gati |
| Kilpest is available at a discount of ~51% to the average P/E ratio of two prominent diagnostic players. Buy for 43% upside: Nuvama | |
| Company: | kilpest |
| Brokerage: | Nuvama |
| Date of report: | September 11, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 43% |
| Summary: | Kilpest India (KLPI) has seen multiple transformations in the last ~50 years of existence. Based in Bhopal, it started with agrochemicals in 1972 and forayed into the niche molecular diagnostics business in FY10 through its subsidiary 3B Black Bio Biotech India |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | kilpest |
| Beta Drugs has delivered a healthy performance. Buy for target price of Rs 1325 (27% upside): Nuvama | |
| Company: | Beta Drugs |
| Brokerage: | Nuvama |
| Date of report: | September 3, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 27% |
| Summary: | Beta Drugs (BETADR) is one of the leading players in the domestic oncology space and ranks among the top 10 in the cytotoxic market. Equipped with three state-of-the-art manufacturing facilities, it produces and markets a wide range of oncology (anti-cancer) drugs, which are available across major government and private hospitals. It expanded, upgraded, and received regulatory approvalsfrom INVIMA (Colombia)/INVISA (Brazil) for its key facilities which will aid exports |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Beta Drugs |
| Atarco acquisition is a win-win deal for Gokaldas Exports. Buy for target price of Rs 884: Nuvama | |
| Company: | Gokaldas Exports |
| Brokerage: | Nuvama |
| Date of report: | August 29, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 20% |
| Summary: | Atarco acquisition a win-win deal Gokaldas Exports (GEXP) has announced the complete acquisition of the Atraco Group (Atraco) for USD55mn. Through this deal, it will gain duty free access to the US and European markets (duties on Indian imports range from 11% to 28%). Atraco has five production units: four/ one in Kenya/Ethiopia, with a […] |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Gokaldas Exports |
| Astral Ltd is superior in every respect; outlook strong. Buy for target price of Rs INR 1,983: Nuvama | |
| Company: | Astral Ltd |
| Brokerage: | Nuvama |
| Date of report: | May 18, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 18% |
| Summary: | We remain positive on ASTRA given its: i) market share gains in the core plastic piping business; ii) strong brand recall; iii) product launches (it recently forayed into faucets and sanitaryware, tanks, infrastructure pipes, DWV piping system, valves, and paints to increase its addressable market); iv) strong cash flow and net debt-free Balance Sheet, with an improvement in working capital; and v) robust growth in the adhesives business |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | astral |